Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.
Journal: Dermatology and therapy
Published: August 04, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.
Journal: The British journal of dermatology
Published: June 25, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.
Journal: The British journal of dermatology
Published: June 25, 2025
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.
Journal: The British journal of dermatology
Published: June 13, 2025
Papular xanthomas with destructive arthritis.
Journal: Journal of the American Academy of Dermatology
Published: June 26, 2013
Uveitis and desquamating rash of the palms and soles.
Journal: The American Journal of dermatopathology
Published: May 22, 2013
Mycobacterium leprae and Mycobacterium haemophilum co-infection in an iatrogenically immunosuppressed patient.
Journal: Diagnostic microbiology and infectious disease
Published: April 29, 2013
Recall dermatitis at patch test sites in alopecia areata treated with diphencyprone.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 02, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026